Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634582 · ClinicalTrials.gov registry record · Phase 2
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00634582 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2 participants.
The verdict
NCT00634582, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE quality-of-life assessment
- OTHER immunoenzyme technique
- DRUG paricalcitol
- PROCEDURE dual x-ray absorptometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634582
The ClinicalTrials.gov registry entry for NCT00634582 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00634582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634582 about?
NCT00634582 is a clinical study titled "Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases". RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and b...
What is the current status of trial NCT00634582?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00634582?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quality-of-life assessment (PROCEDURE), immunoenzyme technique (OTHER), paricalcitol (DRUG), dual x-ray absorptometry (PROCEDURE).
Who is sponsoring clinical trial NCT00634582?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.